Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Total 13F shares
-
520,326
-
Share change
-
-128,733
-
Total reported value
-
$27,921,660
-
Price per share
-
$52.44
-
Number of holders
-
62
-
Value change
-
-$8,352,070
-
Number of buys
-
25
-
Number of sells
-
18
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2025
As of 31 Dec 2025,
CRISPR Therapeutics AG - Common Stock (CRSP) was held by
62 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
520,326 shares.
The largest 10 holders included
Baker Chad R, WEALTH ENHANCEMENT ADVISORY SERVICES, LLC, CONGRESS ASSET MANAGEMENT CO, Green Alpha Advisors, LLC, Hennion & Walsh Asset Management, Inc., Ipswich Investment Management Co., Inc., Perigon Wealth Management, LLC, BRAVE ASSET MANAGEMENT INC, SG Americas Securities, LLC, and SteelPeak Wealth, LLC.
This page lists
63
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.